nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—Aphthous stomatitis—Varenicline—nicotine dependence	0.0163	0.0213	CcSEcCtD
Thalidomide—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0156	0.0203	CcSEcCtD
Thalidomide—Transient ischaemic attack—Varenicline—nicotine dependence	0.0151	0.0198	CcSEcCtD
Thalidomide—Hostility—Varenicline—nicotine dependence	0.0138	0.018	CcSEcCtD
Thalidomide—Sexual dysfunction—Varenicline—nicotine dependence	0.0136	0.0178	CcSEcCtD
Thalidomide—Suicide attempt—Varenicline—nicotine dependence	0.0134	0.0176	CcSEcCtD
Thalidomide—Gastric ulcer—Varenicline—nicotine dependence	0.0131	0.0172	CcSEcCtD
Thalidomide—Platelet count decreased—Varenicline—nicotine dependence	0.0128	0.0168	CcSEcCtD
Thalidomide—Toothache—Varenicline—nicotine dependence	0.0125	0.0164	CcSEcCtD
Thalidomide—Psoriasis—Varenicline—nicotine dependence	0.0121	0.0159	CcSEcCtD
Thalidomide—CYP2E1—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0113	0.065	CbGpPWpGaD
Thalidomide—NFKB1—cardiovascular system—nicotine dependence	0.0113	0.188	CbGeAlD
Thalidomide—Intestinal obstruction—Varenicline—nicotine dependence	0.0112	0.0146	CcSEcCtD
Thalidomide—Menstrual disorder—Varenicline—nicotine dependence	0.0112	0.0146	CcSEcCtD
Thalidomide—Thrombosis—Varenicline—nicotine dependence	0.0108	0.0141	CcSEcCtD
Thalidomide—Nystagmus—Varenicline—nicotine dependence	0.0107	0.014	CcSEcCtD
Thalidomide—Hyperlipidaemia—Varenicline—nicotine dependence	0.0106	0.0138	CcSEcCtD
Thalidomide—Endocrine disorder—Varenicline—nicotine dependence	0.0092	0.012	CcSEcCtD
Thalidomide—Acne—Varenicline—nicotine dependence	0.00906	0.0118	CcSEcCtD
Thalidomide—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00875	0.0501	CbGpPWpGaD
Thalidomide—Accidental injury—Varenicline—nicotine dependence	0.00862	0.0113	CcSEcCtD
Thalidomide—FGFR2—cardiovascular system—nicotine dependence	0.00851	0.141	CbGeAlD
Thalidomide—Viral infection—Varenicline—nicotine dependence	0.00844	0.011	CcSEcCtD
Thalidomide—Thinking abnormal—Varenicline—nicotine dependence	0.00833	0.0109	CcSEcCtD
Thalidomide—Leukocytosis—Varenicline—nicotine dependence	0.00812	0.0106	CcSEcCtD
Thalidomide—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00798	0.0457	CbGpPWpGaD
Thalidomide—Coordination abnormal—Varenicline—nicotine dependence	0.00777	0.0102	CcSEcCtD
Thalidomide—Pulmonary embolism—Varenicline—nicotine dependence	0.00763	0.00997	CcSEcCtD
Thalidomide—Hyperkalaemia—Varenicline—nicotine dependence	0.00749	0.00979	CcSEcCtD
Thalidomide—Eructation—Varenicline—nicotine dependence	0.00749	0.00979	CcSEcCtD
Thalidomide—CRBN—midbrain—nicotine dependence	0.00742	0.123	CbGeAlD
Thalidomide—Dry eye—Varenicline—nicotine dependence	0.00704	0.00921	CcSEcCtD
Thalidomide—CYP2E1—Xenobiotics—CYP2A7—nicotine dependence	0.00703	0.0403	CbGpPWpGaD
Thalidomide—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00702	0.0402	CbGpPWpGaD
Thalidomide—Oesophagitis—Varenicline—nicotine dependence	0.00697	0.00911	CcSEcCtD
Thalidomide—Hypertonia—Varenicline—nicotine dependence	0.00669	0.00874	CcSEcCtD
Thalidomide—CYP1A1—Xenobiotics—CYP2A7—nicotine dependence	0.00663	0.038	CbGpPWpGaD
Thalidomide—Mental disability—Varenicline—nicotine dependence	0.00662	0.00865	CcSEcCtD
Thalidomide—Euphoric mood—Varenicline—nicotine dependence	0.00655	0.00856	CcSEcCtD
Thalidomide—Lymphadenopathy—Varenicline—nicotine dependence	0.00649	0.00848	CcSEcCtD
Thalidomide—Diabetes mellitus—Varenicline—nicotine dependence	0.00637	0.00832	CcSEcCtD
Thalidomide—NFKB1—p75 NTR receptor-mediated signalling—FGD1—nicotine dependence	0.00624	0.0357	CbGpPWpGaD
Thalidomide—Deafness—Varenicline—nicotine dependence	0.00619	0.00809	CcSEcCtD
Thalidomide—Eczema—Varenicline—nicotine dependence	0.00616	0.00805	CcSEcCtD
Thalidomide—Eye pain—Varenicline—nicotine dependence	0.00613	0.00802	CcSEcCtD
Thalidomide—Injury—Varenicline—nicotine dependence	0.00602	0.00787	CcSEcCtD
Thalidomide—Renal failure acute—Varenicline—nicotine dependence	0.006	0.00784	CcSEcCtD
Thalidomide—Libido decreased—Varenicline—nicotine dependence	0.00597	0.0078	CcSEcCtD
Thalidomide—Amnesia—Varenicline—nicotine dependence	0.00589	0.0077	CcSEcCtD
Thalidomide—Increased appetite—Varenicline—nicotine dependence	0.00589	0.0077	CcSEcCtD
Thalidomide—Visual disturbance—Varenicline—nicotine dependence	0.00584	0.00764	CcSEcCtD
Thalidomide—Atrial fibrillation—Varenicline—nicotine dependence	0.00584	0.00764	CcSEcCtD
Thalidomide—Arthritis—Varenicline—nicotine dependence	0.0057	0.00745	CcSEcCtD
Thalidomide—Hypoglycaemia—Varenicline—nicotine dependence	0.00567	0.00741	CcSEcCtD
Thalidomide—Cerebrovascular accident—Varenicline—nicotine dependence	0.00565	0.00738	CcSEcCtD
Thalidomide—Lethargy—Varenicline—nicotine dependence	0.00565	0.00738	CcSEcCtD
Thalidomide—NFKB1—brain—nicotine dependence	0.00556	0.0923	CbGeAlD
Thalidomide—Osteoarthritis—Varenicline—nicotine dependence	0.00554	0.00724	CcSEcCtD
Thalidomide—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00554	0.00724	CcSEcCtD
Thalidomide—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00549	0.00718	CcSEcCtD
Thalidomide—Migraine—Varenicline—nicotine dependence	0.00545	0.00712	CcSEcCtD
Thalidomide—Affect lability—Varenicline—nicotine dependence	0.00545	0.00712	CcSEcCtD
Thalidomide—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00542	0.0311	CbGpPWpGaD
Thalidomide—Psychotic disorder—Varenicline—nicotine dependence	0.00541	0.00707	CcSEcCtD
Thalidomide—Mood swings—Varenicline—nicotine dependence	0.00525	0.00685	CcSEcCtD
Thalidomide—Liver function test abnormal—Varenicline—nicotine dependence	0.00511	0.00668	CcSEcCtD
Thalidomide—Dry skin—Varenicline—nicotine dependence	0.00508	0.00663	CcSEcCtD
Thalidomide—Hypokalaemia—Varenicline—nicotine dependence	0.00504	0.00659	CcSEcCtD
Thalidomide—Breast disorder—Varenicline—nicotine dependence	0.005	0.00654	CcSEcCtD
Thalidomide—Cramp muscle—Varenicline—nicotine dependence	0.00499	0.00652	CcSEcCtD
Thalidomide—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00495	0.0283	CbGpPWpGaD
Thalidomide—Abdominal distension—Varenicline—nicotine dependence	0.00482	0.0063	CcSEcCtD
Thalidomide—Dysphagia—Varenicline—nicotine dependence	0.00479	0.00625	CcSEcCtD
Thalidomide—Angina pectoris—Varenicline—nicotine dependence	0.00466	0.00609	CcSEcCtD
Thalidomide—CRBN—brain—nicotine dependence	0.00466	0.0774	CbGeAlD
Thalidomide—Bronchitis—Varenicline—nicotine dependence	0.0046	0.00601	CcSEcCtD
Thalidomide—Pollakiuria—Varenicline—nicotine dependence	0.00442	0.00578	CcSEcCtD
Thalidomide—Erectile dysfunction—Varenicline—nicotine dependence	0.00441	0.00576	CcSEcCtD
Thalidomide—Photosensitivity reaction—Varenicline—nicotine dependence	0.00437	0.00571	CcSEcCtD
Thalidomide—Weight increased—Varenicline—nicotine dependence	0.00436	0.00569	CcSEcCtD
Thalidomide—Hyperglycaemia—Varenicline—nicotine dependence	0.00432	0.00564	CcSEcCtD
Thalidomide—Infestation NOS—Varenicline—nicotine dependence	0.00427	0.00558	CcSEcCtD
Thalidomide—Infestation—Varenicline—nicotine dependence	0.00427	0.00558	CcSEcCtD
Thalidomide—Depression—Varenicline—nicotine dependence	0.00425	0.00556	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00423	0.00553	CcSEcCtD
Thalidomide—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00423	0.0242	CbGpPWpGaD
Thalidomide—Acute coronary syndrome—Varenicline—nicotine dependence	0.00421	0.0055	CcSEcCtD
Thalidomide—Myocardial infarction—Varenicline—nicotine dependence	0.00418	0.00547	CcSEcCtD
Thalidomide—FGFR2—brain—nicotine dependence	0.00418	0.0694	CbGeAlD
Thalidomide—Stomatitis—Varenicline—nicotine dependence	0.00416	0.00544	CcSEcCtD
Thalidomide—Conjunctivitis—Varenicline—nicotine dependence	0.00415	0.00542	CcSEcCtD
Thalidomide—Epistaxis—Varenicline—nicotine dependence	0.00402	0.00526	CcSEcCtD
Thalidomide—Sinusitis—Varenicline—nicotine dependence	0.004	0.00523	CcSEcCtD
Thalidomide—Bradycardia—Varenicline—nicotine dependence	0.0039	0.0051	CcSEcCtD
Thalidomide—Hypoaesthesia—Varenicline—nicotine dependence	0.00381	0.00498	CcSEcCtD
Thalidomide—Urinary tract disorder—Varenicline—nicotine dependence	0.00378	0.00494	CcSEcCtD
Thalidomide—Oedema peripheral—Varenicline—nicotine dependence	0.00377	0.00493	CcSEcCtD
Thalidomide—Urethral disorder—Varenicline—nicotine dependence	0.00375	0.00491	CcSEcCtD
Thalidomide—Visual impairment—Varenicline—nicotine dependence	0.00369	0.00482	CcSEcCtD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00367	0.021	CbGpPWpGaD
Thalidomide—Erythema multiforme—Varenicline—nicotine dependence	0.00362	0.00473	CcSEcCtD
Thalidomide—Eye disorder—Varenicline—nicotine dependence	0.00358	0.00468	CcSEcCtD
Thalidomide—Tinnitus—Varenicline—nicotine dependence	0.00357	0.00467	CcSEcCtD
Thalidomide—Cardiac disorder—Varenicline—nicotine dependence	0.00355	0.00465	CcSEcCtD
Thalidomide—Angiopathy—Varenicline—nicotine dependence	0.00348	0.00454	CcSEcCtD
Thalidomide—Immune system disorder—Varenicline—nicotine dependence	0.00346	0.00452	CcSEcCtD
Thalidomide—Mediastinal disorder—Varenicline—nicotine dependence	0.00345	0.00451	CcSEcCtD
Thalidomide—Chills—Varenicline—nicotine dependence	0.00344	0.00449	CcSEcCtD
Thalidomide—Arrhythmia—Varenicline—nicotine dependence	0.00342	0.00447	CcSEcCtD
Thalidomide—Mental disorder—Varenicline—nicotine dependence	0.00336	0.00439	CcSEcCtD
Thalidomide—Malnutrition—Varenicline—nicotine dependence	0.00333	0.00436	CcSEcCtD
Thalidomide—Flatulence—Varenicline—nicotine dependence	0.00329	0.00429	CcSEcCtD
Thalidomide—Dysgeusia—Varenicline—nicotine dependence	0.00327	0.00427	CcSEcCtD
Thalidomide—Back pain—Varenicline—nicotine dependence	0.00323	0.00422	CcSEcCtD
Thalidomide—Muscle spasms—Varenicline—nicotine dependence	0.00321	0.00419	CcSEcCtD
Thalidomide—PTGS1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00317	0.0181	CbGpPWpGaD
Thalidomide—Vision blurred—Varenicline—nicotine dependence	0.00314	0.00411	CcSEcCtD
Thalidomide—Tremor—Varenicline—nicotine dependence	0.00312	0.00408	CcSEcCtD
Thalidomide—NFKB1—TCR Signaling Pathway—OPRM1—nicotine dependence	0.00311	0.0178	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Varenicline—nicotine dependence	0.00309	0.00404	CcSEcCtD
Thalidomide—Anaemia—Varenicline—nicotine dependence	0.00308	0.00403	CcSEcCtD
Thalidomide—Agitation—Varenicline—nicotine dependence	0.00306	0.004	CcSEcCtD
Thalidomide—Angioedema—Varenicline—nicotine dependence	0.00305	0.00398	CcSEcCtD
Thalidomide—Malaise—Varenicline—nicotine dependence	0.00301	0.00393	CcSEcCtD
Thalidomide—Vertigo—Varenicline—nicotine dependence	0.003	0.00392	CcSEcCtD
Thalidomide—Syncope—Varenicline—nicotine dependence	0.00299	0.00391	CcSEcCtD
Thalidomide—CYP2C9—cardiovascular system—nicotine dependence	0.00296	0.0492	CbGeAlD
Thalidomide—Palpitations—Varenicline—nicotine dependence	0.00295	0.00385	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00294	0.0168	CbGpPWpGaD
Thalidomide—Loss of consciousness—Varenicline—nicotine dependence	0.00293	0.00383	CcSEcCtD
Thalidomide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00292	0.0167	CbGpPWpGaD
Thalidomide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00291	0.0167	CbGpPWpGaD
Thalidomide—Cough—Varenicline—nicotine dependence	0.00291	0.0038	CcSEcCtD
Thalidomide—Convulsion—Varenicline—nicotine dependence	0.00289	0.00378	CcSEcCtD
Thalidomide—CYP2E1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00288	0.0165	CbGpPWpGaD
Thalidomide—Hypertension—Varenicline—nicotine dependence	0.00288	0.00376	CcSEcCtD
Thalidomide—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00287	0.0165	CbGpPWpGaD
Thalidomide—Myalgia—Varenicline—nicotine dependence	0.00284	0.00371	CcSEcCtD
Thalidomide—Chest pain—Varenicline—nicotine dependence	0.00284	0.00371	CcSEcCtD
Thalidomide—Arthralgia—Varenicline—nicotine dependence	0.00284	0.00371	CcSEcCtD
Thalidomide—Anxiety—Varenicline—nicotine dependence	0.00283	0.0037	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00282	0.00368	CcSEcCtD
Thalidomide—CYP2E1—cardiovascular system—nicotine dependence	0.00281	0.0466	CbGeAlD
Thalidomide—Discomfort—Varenicline—nicotine dependence	0.0028	0.00367	CcSEcCtD
Thalidomide—Dry mouth—Varenicline—nicotine dependence	0.00278	0.00363	CcSEcCtD
Thalidomide—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00275	0.0158	CbGpPWpGaD
Thalidomide—Oedema—Varenicline—nicotine dependence	0.00272	0.00356	CcSEcCtD
Thalidomide—CYP1A1—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00272	0.0156	CbGpPWpGaD
Thalidomide—PTGS1—cardiovascular system—nicotine dependence	0.00271	0.0449	CbGeAlD
Thalidomide—Infection—Varenicline—nicotine dependence	0.0027	0.00353	CcSEcCtD
Thalidomide—Shock—Varenicline—nicotine dependence	0.00268	0.0035	CcSEcCtD
Thalidomide—Nervous system disorder—Varenicline—nicotine dependence	0.00267	0.00349	CcSEcCtD
Thalidomide—Thrombocytopenia—Varenicline—nicotine dependence	0.00266	0.00348	CcSEcCtD
Thalidomide—Tachycardia—Varenicline—nicotine dependence	0.00266	0.00347	CcSEcCtD
Thalidomide—Skin disorder—Varenicline—nicotine dependence	0.00264	0.00345	CcSEcCtD
Thalidomide—Hyperhidrosis—Varenicline—nicotine dependence	0.00263	0.00344	CcSEcCtD
Thalidomide—Anorexia—Varenicline—nicotine dependence	0.00259	0.00339	CcSEcCtD
Thalidomide—PTGS2—cardiovascular system—nicotine dependence	0.00259	0.0429	CbGeAlD
Thalidomide—Hypotension—Varenicline—nicotine dependence	0.00254	0.00332	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00248	0.00324	CcSEcCtD
Thalidomide—Insomnia—Varenicline—nicotine dependence	0.00246	0.00322	CcSEcCtD
Thalidomide—Dyspnoea—Varenicline—nicotine dependence	0.00243	0.00317	CcSEcCtD
Thalidomide—Somnolence—Varenicline—nicotine dependence	0.00242	0.00316	CcSEcCtD
Thalidomide—Dyspepsia—Varenicline—nicotine dependence	0.0024	0.00313	CcSEcCtD
Thalidomide—CYP2E1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00237	0.0136	CbGpPWpGaD
Thalidomide—Decreased appetite—Varenicline—nicotine dependence	0.00237	0.00309	CcSEcCtD
Thalidomide—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00236	0.0135	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00235	0.00307	CcSEcCtD
Thalidomide—Fatigue—Varenicline—nicotine dependence	0.00235	0.00307	CcSEcCtD
Thalidomide—Constipation—Varenicline—nicotine dependence	0.00233	0.00304	CcSEcCtD
Thalidomide—Pain—Varenicline—nicotine dependence	0.00233	0.00304	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—FGD1—nicotine dependence	0.0023	0.0132	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00229	0.0131	CbGpPWpGaD
Thalidomide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00225	0.0129	CbGpPWpGaD
Thalidomide—Feeling abnormal—Varenicline—nicotine dependence	0.00224	0.00293	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00224	0.0128	CbGpPWpGaD
Thalidomide—CYP1A1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00223	0.0128	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Varenicline—nicotine dependence	0.00223	0.00291	CcSEcCtD
Thalidomide—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00222	0.0127	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00219	0.0126	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—FGD1—nicotine dependence	0.00218	0.0125	CbGpPWpGaD
Thalidomide—Urticaria—Varenicline—nicotine dependence	0.00216	0.00283	CcSEcCtD
Thalidomide—Abdominal pain—Varenicline—nicotine dependence	0.00215	0.00281	CcSEcCtD
Thalidomide—Body temperature increased—Varenicline—nicotine dependence	0.00215	0.00281	CcSEcCtD
Thalidomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00205	0.0118	CbGpPWpGaD
Thalidomide—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00203	0.0116	CbGpPWpGaD
Thalidomide—PTGS2—midbrain—nicotine dependence	0.00202	0.0335	CbGeAlD
Thalidomide—Hypersensitivity—Varenicline—nicotine dependence	0.002	0.00262	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00196	0.0112	CbGpPWpGaD
Thalidomide—Asthenia—Varenicline—nicotine dependence	0.00195	0.00255	CcSEcCtD
Thalidomide—Pruritus—Varenicline—nicotine dependence	0.00193	0.00252	CcSEcCtD
Thalidomide—Diarrhoea—Varenicline—nicotine dependence	0.00186	0.00243	CcSEcCtD
Thalidomide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00183	0.0105	CbGpPWpGaD
Thalidomide—Dizziness—Varenicline—nicotine dependence	0.0018	0.00235	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00178	0.0102	CbGpPWpGaD
Thalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00175	0.0101	CbGpPWpGaD
Thalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00173	0.00992	CbGpPWpGaD
Thalidomide—Vomiting—Varenicline—nicotine dependence	0.00173	0.00226	CcSEcCtD
Thalidomide—Rash—Varenicline—nicotine dependence	0.00172	0.00224	CcSEcCtD
Thalidomide—Dermatitis—Varenicline—nicotine dependence	0.00171	0.00224	CcSEcCtD
Thalidomide—Headache—Varenicline—nicotine dependence	0.0017	0.00223	CcSEcCtD
Thalidomide—PTGS1—Biological oxidations—CYP2A7—nicotine dependence	0.00168	0.00963	CbGpPWpGaD
Thalidomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00166	0.00953	CbGpPWpGaD
Thalidomide—Nausea—Varenicline—nicotine dependence	0.00162	0.00211	CcSEcCtD
Thalidomide—CYP1A1—brain—nicotine dependence	0.00151	0.0251	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00149	0.00855	CbGpPWpGaD
Thalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00142	0.00815	CbGpPWpGaD
Thalidomide—CYP2E1—brain—nicotine dependence	0.00138	0.0229	CbGeAlD
Thalidomide—TNF—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00136	0.00777	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00133	0.00764	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00133	0.00762	CbGpPWpGaD
Thalidomide—PTGS1—brain—nicotine dependence	0.00133	0.022	CbGeAlD
Thalidomide—PTGS2—brain—nicotine dependence	0.00127	0.0211	CbGeAlD
Thalidomide—CYP1A1—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00126	0.0072	CbGpPWpGaD
Thalidomide—CYP2E1—Biological oxidations—CYP2A7—nicotine dependence	0.00126	0.0072	CbGpPWpGaD
Thalidomide—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00125	0.00718	CbGpPWpGaD
Thalidomide—CYP2E1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00124	0.0071	CbGpPWpGaD
Thalidomide—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00124	0.00709	CbGpPWpGaD
Thalidomide—CYP1A1—Biological oxidations—CYP2A7—nicotine dependence	0.00119	0.00679	CbGpPWpGaD
Thalidomide—CYP1A1—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00117	0.00669	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00103	0.00589	CbGpPWpGaD
Thalidomide—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00097	0.00555	CbGpPWpGaD
Thalidomide—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000956	0.00548	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000938	0.00537	CbGpPWpGaD
Thalidomide—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000884	0.00506	CbGpPWpGaD
Thalidomide—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000872	0.00499	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—WASF2—nicotine dependence	0.000816	0.00467	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000802	0.00459	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—WASF1—nicotine dependence	0.000782	0.00448	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—WASF2—nicotine dependence	0.000774	0.00443	CbGpPWpGaD
Thalidomide—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000756	0.00433	CbGpPWpGaD
Thalidomide—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000745	0.00427	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—WASF1—nicotine dependence	0.000742	0.00425	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TAS2R16—nicotine dependence	0.000629	0.0036	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TAS2R16—nicotine dependence	0.000597	0.00342	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKR1B10—nicotine dependence	0.000591	0.00338	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGD1—nicotine dependence	0.000493	0.00283	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF2—nicotine dependence	0.000475	0.00272	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGD1—nicotine dependence	0.000468	0.00268	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—WASF1—nicotine dependence	0.000455	0.00261	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF2—nicotine dependence	0.000451	0.00258	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKR1B10—nicotine dependence	0.000436	0.0025	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—WASF1—nicotine dependence	0.000432	0.00247	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKR1B10—nicotine dependence	0.000414	0.00237	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF2—nicotine dependence	0.000307	0.00176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—WASF1—nicotine dependence	0.000294	0.00169	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKR1B10—nicotine dependence	0.000293	0.00168	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF2—nicotine dependence	0.000291	0.00167	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP2A7—nicotine dependence	0.000288	0.00165	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—WASF1—nicotine dependence	0.000279	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—OPRM1—nicotine dependence	0.000265	0.00152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—OPRM1—nicotine dependence	0.000252	0.00144	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2A7—nicotine dependence	0.000228	0.00131	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2A7—nicotine dependence	0.000215	0.00123	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000215	0.00123	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2A7—nicotine dependence	0.000203	0.00116	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DRD2—nicotine dependence	0.000192	0.0011	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DRD2—nicotine dependence	0.000182	0.00104	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000166	0.00095	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000151	0.000866	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000129	0.00074	CbGpPWpGaD
